Advertisement
  • Advocacy in Action

    Leaving a Legacy

    Two mothers, each with a son who died of brain cancer, worked together to increase awareness and acceptance of tumor tissue donation.

    by Esther Landhuis

  • Forward Look

    What’s Next? Spring 2020

    A new way to detect Barrett's esophagus.

    by Bradley Jones

  • A Unified Strategy

    A couple who lost their daughter to brain cancer builds a charity that connects parents, hospitals and researchers with data.

    by Marci A. Landsmann

  • Medicare Coverage for Next-Generation Sequencing Tests

    Multigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.

    by Ashley P. Taylor

  • For Prostate Biopsy, It’s Best to Combine Old and New Methods

    Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.

    by Kate Yandell

  • On Cancer and Identity

    The first time Liza Bernstein was diagnosed with cancer, she wouldn't allow it to be part of her identity. After her third cancer diagnosis, she became an advocate for other patients.

    by Liza Bernstein

  • Despite Generic Imatinib, Cost of Treating CML Remains High

    The arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.

    by Anna Azvolinsky

  • Nothing but Time

    A father with metastatic kidney cancer embraces moments with his 3-year-old son while pondering how he'll be remembered.

    by Adam P. Stern

  • When Cancer Becomes an Unwanted Priority

    Amanda Rose Ferraro's leukemia diagnosis forced her to spend time at the hospital away from her 3-year-old-son. She calls focusing on her health and leaving her son “the hardest thing I have ever had to do.”

    by Amanda Rose Ferraro

  • New Drugs for an Elusive Cancer Target

    Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.

    by Anna Azvolinsky